Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

3 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
7(63.6%)
Phase 3
3(27.3%)
Phase 1
1(9.1%)
11Total
Phase 2(7)
Phase 3(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT04166565Phase 2Active Not Recruiting

Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease

Role: lead

NCT05257083Phase 3Active Not Recruiting

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Role: lead

NCT03710603Phase 3Active Not Recruiting

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

Role: lead

NCT03180736Phase 3Completed

Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex

Role: lead

NCT04617925Phase 2Completed

A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis

Role: lead

NCT03896737Phase 2Active Not Recruiting

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Role: lead

NCT04131309Phase 2Completed

A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

Role: lead

NCT04564703Phase 2Active Not Recruiting

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

Role: lead

NCT06183489Phase 2Recruiting

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Role: lead

NCT06189833Phase 2Recruiting

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS

Role: lead

NCT04492371Completed

COVID-19 Infection and Multiple Myeloma

Role: lead

NCT02056756Phase 1Completed

Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma

Role: lead

All 12 trials loaded